日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma

将MCL-1抑制剂与CD37靶向嵌合抗原受体T细胞相结合,是治疗T细胞淋巴瘤的有效策略。

Heavican-Foral, Tayla B; Korell, Felix; Scarfò, Irene; Wiggers, Caroline R M; B, Allen Thayakumar; Eisenbies, Zachary; Powers, Foster; Hegel, Justin; Liu, Jianlin; Kulp, Steffen; Silva, Harrison; Wu, Gongwei; Letai, Anthony; Stegmaier, Kimberly; Lohr, Jens G; Weinstock, David M; Maus, Marcela V; Knoechel, Birgit

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors

CDK8 抑制的转录拮抗作用可提高 MEK 抑制剂的治疗效果

Clare F Malone #, Minjee Kim #, Gabriela Alexe, Kathleen Engel, Alexandra B Forman, Amanda Robichaud, Amy Saur Conway, Amy Goodale, Ashleigh Meyer, Delan Khalid, Allen Thayakumar, John M Hatcher, Nathanael S Gray, Federica Piccioni, Kimberly Stegmaier

Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

使用捕捉肿瘤异质性的体外平台预测抗癌药物的临床反应

Biswanath Majumder, Ulaganathan Baraneedharan, Saravanan Thiyagarajan, Padhma Radhakrishnan, Harikrishna Narasimhan, Muthu Dhandapani, Nilesh Brijwani, Dency D Pinto, Arun Prasath, Basavaraja U Shanthappa, Allen Thayakumar, Rajagopalan Surendran, Govind K Babu, Ashok M Shenoy, Moni A Kuriakose, Guil